Browse by Phase
Phase 2 Clinical Trials
Phase 2 trials study whether a drug works in people with a specific disease or condition. These studies enroll 100–300 participants and also continue to evaluate safety.
Total Trials
1,078
Recruiting Now
1,078
Top Conditions in Phase 2
Frequently Asked Questions — Phase 2 Trials
What does a Phase 2 clinical trial evaluate?
Phase 2 trials assess whether a drug or treatment works in people with a specific disease or condition. Enrolling 100–300 participants, these studies collect preliminary efficacy data while continuing to monitor safety and identify the optimal dosing regimen. A successful Phase 2 outcome is required to advance to large-scale Phase 3 testing.
How long do Phase 2 trials typically take?
Phase 2 clinical trials typically run for 1–4 years, depending on the condition, endpoint complexity, and enrollment rate. Rare disease trials or those with long-term outcome measures may run longer. Many sponsors run Phase 2 studies at multiple sites simultaneously to accelerate recruitment.
Who can participate in a Phase 2 clinical trial?
Eligibility for Phase 2 trials is defined by specific inclusion and exclusion criteria. Participants are typically patients diagnosed with the condition under study and may or may not have received prior treatment. Age, disease stage, comorbidities, and laboratory values are common eligibility factors. Review each trial's criteria on ClinicalTrials.gov for specific requirements.
Active Phase 2 Studies
NCT07811726 Phase 2
Recruiting
The Purpose of This Study is to Evaluate Efficacy and Safety of NT-101 Eye Drops...
Condition
Wet Age Related Macular Degeneration
Enrollment
66 pts
Location
United States
Sponsor
NexThera Co., Ltd.
NCT07806617 Phase 2
Recruiting
Intralesional Gardasil-9 for the Treatment of Recalcitrant Warts
Condition
Warts
Enrollment
55 pts
Location
United States
Sponsor
Rush University Medical Center
NCT06654440 Phase 2
Recruiting
A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy
Condition
Advanced Gynecological Malignancy
Enrollment
100 pts
Location
China
Sponsor
Shanghai Hengrui Pharmaceutica
NCT06494891 Phase 2
Recruiting
Motivation for IV Alcohol Self-Administration in Humans
Condition
Alcohol Use Disorder
Enrollment
210 pts
Location
United States
Sponsor
University of California, Los
NCT05422690 Phase 2
Recruiting
The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin...
Condition
Intrahepatic Cholangiocarcinoma
Enrollment
16 pts
Location
United States
Sponsor
Inova Health Care Services
NCT07046910 Phase 2
Recruiting
Developing Hyperpolarized Gas MRI Signatures to Detect and Manage Acute Cellular...
Condition
Lung Transplant Rejection
Enrollment
60 pts
Location
United States
Sponsor
University of Virginia
NCT07085338 Phase 2
Recruiting
A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunot...
Condition
Neuroblastoma Recurrent
Enrollment
54 pts
Location
United States
Sponsor
St. Jude Children's Research H
NCT06302491 Phase 2
Recruiting
A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia
Condition
β -Thalassemia
Enrollment
64 pts
Location
China
Sponsor
Kind Pharmaceuticals LLC
NCT07006506 Phase 2
Recruiting
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease...
Condition
Graft Versus Host Disease
Enrollment
46 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance
NCT06961006 Phase 2
Recruiting
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in Pe...
Condition
Malignant Melanoma
Enrollment
160 pts
Location
United States, Australia, Canada
Sponsor
Merck Sharp & Dohme LLC
NCT07297004 Phase 2
Recruiting
Stereotactic Body Radiation Therapy for Unresectable Locally Recurrent Rectal Ca...
Condition
Unresectable Locally Recurrent Rectal Cancer
Enrollment
20 pts
Location
China
Sponsor
Sixth Affiliated Hospital, Sun
NCT07509749 Phase 2
Recruiting
Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)
Condition
GVHD, Acute
Enrollment
54 pts
Location
China
Sponsor
Daihong Liu
NCT06660355 Phase 2
Recruiting
Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Thera...
Condition
Chronic Graft-versus-host Disease (cGVHD)
Enrollment
120 pts
Location
United States
Sponsor
H. Lee Moffitt Cancer Center a
NCT07254585 Phase 2
Recruiting
SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squa...
Condition
Head and Neck Squamous Cell Carcinoma
Enrollment
70 pts
Location
China
Sponsor
CSPC Megalith Biopharmaceutica
NCT02693535 Phase 2
Recruiting
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That...
Condition
Lymphoma, Non-Hodgkin
Enrollment
4,200 pts
Location
United States, Puerto Rico
Sponsor
American Society of Clinical O
NCT07538635 Phase 2
Recruiting
CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Ly...
Condition
High-risk R/R LBCL
Enrollment
20 pts
Location
China
Sponsor
Zhejiang Cancer Hospital
NCT06554717 Phase 2
Recruiting
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
Condition
HIV-1-infection
Enrollment
100 pts
Location
United States
Sponsor
Massachusetts General Hospital
NCT06773910 Phase 2
Recruiting
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lu...
Condition
Limited Stage Small Cell Lung Cancer
Enrollment
250 pts
Location
United States
Sponsor
SCRI Development Innovations,
NCT06617923 Phase 2
Recruiting
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associate...
Condition
Ovary Cancer
Enrollment
18 pts
Location
United States
Sponsor
Sidney Kimmel Comprehensive Ca
NCT05842512 Phase 2
Recruiting
Study of ADI-PEG 20 Versus Placebo in Subjects With NASH
Condition
Nonalcoholic Steatohepatitis (NASH)
Enrollment
60 pts
Location
Taiwan
Sponsor
Polaris Group
NCT05893381 Phase 2
Recruiting
Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Can...
Condition
Prostate Cancer
Enrollment
70 pts
Location
Italy
Sponsor
Istituto Romagnolo per lo Stud
NCT07493265 Phase 2
Recruiting
A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
Condition
Narcolepsy
Enrollment
64 pts
Location
United States, Belgium, Canada
Sponsor
Eisai Inc.
NCT05785065 Phase 2
Recruiting
Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung D...
Condition
Systemic Sclerosis With Lung Involvement
Enrollment
35 pts
Location
Canada
Sponsor
Centre hospitalier de l'Univer
NCT06248671 Phase 2
Recruiting
Prophylactic Treatment With Atorvastatin for Episodic Migraine.
Condition
Episodic Migraine
Enrollment
450 pts
Location
Norway
Sponsor
St. Olavs Hospital
NCT07288333 Phase 2
Recruiting
Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
Condition
Schizophrenia
Enrollment
120 pts
Location
Bulgaria, Romania, United Kingdom
Sponsor
Neurocrine Biosciences
Page 1 of 44 — 1,078 trials total
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology